Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Other Operating Expenses (2017 - 2025)

Historic Other Operating Expenses for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $2.5 million.

  • Aclaris Therapeutics' Other Operating Expenses fell 2054.24% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.6 million, marking a year-over-year increase of 322297.63%. This contributed to the annual value of $104.9 million for FY2024, which is 488826.48% up from last year.
  • As of Q3 2025, Aclaris Therapeutics' Other Operating Expenses stood at $2.5 million, which was down 2054.24% from $3.4 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Other Operating Expenses high stood at $94.9 million for Q4 2024, and its period low was -$13.2 million during Q4 2023.
  • Moreover, its 5-year median value for Other Operating Expenses was $3.2 million (2024), whereas its average is $8.2 million.
  • Over the last 5 years, Aclaris Therapeutics' Other Operating Expenses had its largest YoY gain of 247555.56% in 2023, and its largest YoY loss of 25373.81% in 2023.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Other Operating Expenses stood at $3.3 million in 2021, then soared by 157.21% to $8.6 million in 2022, then crashed by 253.74% to -$13.2 million in 2023, then skyrocketed by 816.65% to $94.9 million in 2024, then plummeted by 97.31% to $2.5 million in 2025.
  • Its Other Operating Expenses stands at $2.5 million for Q3 2025, versus $3.4 million for Q2 2025 and $1.8 million for Q1 2025.